ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO143

Treatment Patterns for Low-Risk Prostate Cancer in Dialysis, Kidney Transplant, and Non-Dialysis

Session Information

Category: Onconephrology

  • 1600 Onconephrology

Authors

  • Sarabu, Nagaraju, University Hospitals, Cleveland, Ohio, United States
  • Dong, Weichuan, Case Western Reserve University, Cleveland, Ohio, United States
  • Koroukian, Siran M., Case Western Reserve University, Cleveland, Ohio, United States
Background

Patients with end stage kidney disease being evaluated for transplant are screened for prostate cancer. When a cancer is found, it is often treated given concerns about transplant eligibility in the presence of a malignancy.

Methods

Retrospective population based observational cohort study, using Surveillance, Epidemiology, and End Results-Medicare data (Males > 40 years with localized prostate cancer (2010 – 2015). Compared low risk localized prostate cancer treatment patterns and mortality rates among dialysis, kidney transplant and non-dialysis patients using logistic regression and cox proportional hazards models.

Results

A total of 46 low risk prostate cancer dialysis patients and 20 kidney transplant patients were identified. We age-matched 42 dialysis patients to 210 non-dialysis patients (Table 1). Non-dialysis patients with low-risk prostate cancer were less likely, OR: 0.080.270.8 to get curative treatment, and high mortality, as compared to dialysis patients. None of the kidney transplant patients in low-risk group died of prostate cancer.

Conclusion

Dialysis patients, who are more likely to die of other causes, are paradoxically more likely to be treated for low-risk prostate cancer. Active surveillance should be performed in this population, and should not preclude transplant eligibility.

Baseline Characteristics. Numbers < 11 are masked according to SEER-Medicare policy.